CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a vaccine platform targeting the HIV gp41 protein to elicit neutralizing antibodies. By designing immunogens that mimic gp41's fusion intermediate conformations, the project seeks to enhance the immune response against HIV, particularly at mucosal sites, to prevent infection.
There is now an increasingly solid body of scientific evidence which demonstrates that the binding of small molecular weight compounds, peptides and antibodies (Abs) to fusion-intermediate conformations of gp41 leads to an inhibition of HIV cell entry.
The principal aim of this project is to exploit this information by establishing a platform where gp41-derived vaccine candidates will be designed to elicit neutralising Abs.
Several families of immunogens which mimic gp41 in its fusion intermedia…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Berlin
Type: Research institute
Activity type: Research Organisations
SME: No
Spain, Granada
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, REGENSBURG
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
